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Abstract: Herbal and dietary supplements (HDS) have been used for health-related purposes since more
than 5000 years, and their application is firmly anchored in all societies worldwide. Over last decades, a
remarkable renaissance in the use of HDS can be noticed in affluent societies for manifold reasons. HDS
are forms of complementary and alternative medicines commonly used to prevent or treat diseases, or
simply as a health tonic. Another growing indication for HDS is their alleged benefit for weight loss or
to increase physical fitness. Access is easy via internet and mail-order pharmacies, and their turnover
reaches billions of dollars in the USA and Europe alone. However, HDS are generally not categorized
as drugs and thus less strictly regulated in most countries. As a result, scientific evidence proving
their beneficial effects is mostly lacking, although some HDS may have purported benefits. However,
the majority lacks such proof of value, and their use is predominantly based on belief and hope. In
addition to missing scientific evidence supporting their use, HDS are typically prone to batch-to-batch
variability in composition and concentration, contamination, and purposeful adulteration. Moreover,
numerous examples of preparations emerged which have been linked to significant liver injury. These
include single ingredients, such as kava, germander, and several Chinese herbals. Other HDS products
associated with liver toxicity consist of multiple, often ill-defined ingredients, such as Hydroxycut and
Herbalife. Affirmative diagnostic tests are not available, and the assessment of liver injury ascribed to
HDS depends on a thorough and proactive medical history, careful exclusion of other causes, and a search
for available reports on similar events linked to the intake of the suspected preparation or ingredients
contained therein.
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and several Chinese herbals. Other HDS products associ-
ated with liver toxicity consist of multiple, often ill-defined 
ingredients, such as Hydroxycut and Herbalife. Affirma-
tive diagnostic tests are not available, and the assessment 
of liver injury ascribed to HDS depends on a thorough 
and proactive medical history, careful exclusion of other 
causes, and a search for available reports on similar events 
linked to the intake of the suspected preparation or ingredi-
ents contained therein.
Keywords Complementary medicine · Drug-induced 
liver injury · Hepatitis · Liver failure
Introduction
Despite the progress of mainstream medicine in the last 
decades, a stupendous increase in the popularity of herbal 
and dietary supplements (HDS) has been recorded. A 
national telephone survey in the USA first undertaken 
in 1990 demonstrated a sharp rise in the consumption of 
HDS from 2.5 to 12.1 % in 1997 when the interview was 
repeated (Eisenberg et al. 1993, 1998). Similar figures 
exist for Europe where the use of herbals varies consider-
ably between studies, but outscores all other complemen-
tary medicine approaches (Posadzki et al. 2013; Eardley 
et al. 2012). Marignani and colleagues investigated the 
proportion of patients with hepatobiliary disorders taking 
HDS and patients’ attitudes toward such interventions and 
found more than one-third of subjects admitting the use 
of HDS, often complementary to conventional medication 
(Marignani et al. 2010). Even higher figures were found in 
an inquiry within six liver disease clinics across the USA 
which revealed that up to 65 % of patients with liver disease 
take HDS (Strader et al. 2002). Many factors contribute to 
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herbal medicine’s appeal. A positive aspect may be that it 
reflects an increased awareness toward health and well-
being in general, but the expectations toward the purported 
virtues of HDS are as numerous as the diverse groups of 
users. In declining order of prevalence, they included hope 
to influence the natural history of a given disease, disease 
prevention and the promotion of health/general well-being, 
reduction of side effects of other drugs, retain control over 
one’s health, improvement of symptoms, boosting the 
immune system, emotional support, holistic care, improv-
ing quality of life, good therapeutic relationship, obtain-
ing information, coping better with illness, supporting the 
natural healing process, and availability of treatment (Ernst 
and Hung 2011). These motivations reflect a deep belief 
that HDS are safe because they are “natural,” and fit into 
the image of a gentle and, therefore, harmless alternative 
to conventional medicine. Even more so, patients are often 
dissatisfied with the latter because of suboptimal treatment 
success or adverse effects. In addition, HDS are usually 
excluded from tight prescription regulations and thus can 
be easily purchased in pharmacies, health stores, gyms, 
and more recently from internet sources, and are relatively 
inexpensive.
Although there is vague evidence for efficacy of most 
HDS, there is unquestionable proof that such agents are 
sometimes responsible for causing liver injury, very much 
in contrast to the belief of users. Hepatotoxicity caused by 
complementary and alternative medicines was one of the 
two most common etiologies reported among 24,112 Chi-
nese patients with DILI (Zhou et al. 2013). A tabular com-
pilation of the numerous case reports on herbs and herbal 
products associated with hepatotoxicity can be found in 
(Teschke et al. 2012) and in Table 1. In the absence of 
regulatory guidelines, the true incidence of hepatotoxic-
ity from HDS is not known. Published evidence predomi-
nantly relies on sporadic reporting, and proper pharma-
covigilance—such as with synthetic drugs—is not in 
place. The widespread use of HDS is largely uncontrolled, 
and unawareness of consumers and healthcare providers 
toward their potential dangers likely causes significant 
under-reporting. A relatively low proportion of 2 % of 
cases of DILI in a Spanish report was ascribed to HDS 
(García-Cortés et al. 2008), whereas the US Drug-Induced 
Liver Injury Network (DILIN) found 10 % of cases attrib-
utable to HDS (Chalasani et al. 2008). A more recent 
study by the same DILIN investigators scrutinized hepa-
totoxicity from HDS and its outcomes versus that of con-
ventional medications among patients enrolled between 
2004 and 2013. Among the 839 patients recruited with 
DILI, 130 (15.5 %) were judged to have experienced liver 
injury due to HDS. Liver injury due to HDS increased 
from 7 to 20 % (p < 0.001) during the study period and 
more frequently led to death or transplantation compared 
to injury from conventional medications (13 vs. 3 %, 
p < 0.05) (Navarro et al. 2014). The latter observation fits 
to data from two small series of patients progressing to 
hepatic failure. These include 20 US patients with liver 
failure of whom 35 % were considered the result of HDS 
intake (Estes et al. 2003), and 30 patients from China all 
of whom diagnosed with acute liver failure associated 
with intake of traditional Chinese medicines (Zhao et al. 
2014).
In the light of these data, the present review provides an 
updated summary on the topic to emphasize the possibility 
of HDS as a potential cause of liver injury, and guidance on 
how to manage a clinical case in which this is suspected.
Diagnostic and causality assessment of HDS-associated 
liver injury
Awareness toward liver injury from conventional drugs is 
well rooted among most medical professionals, whereas 
HDS as a potential etiology has only recently been recog-
nized, although they may present with the same spectrum 
of liver pathologies as synthetic products. Diagnosis is—
as with conventional medication—difficult and requires a 
significant degree of suspicion from the assessor, but cli-
nicians often do not think of HDS as a potential cause of 
liver damage, and thus fail to inquire their use. In addition, 
willingness of patients to be forthcoming about the use of 
such products is low, either because they do not consider 
them potentially harmful, or because they fear not to be 
taken seriously by the physician. Thus, in many published 
reports, herbals are only classified as the true cause after 
repeated questioning. No specific diagnostic test or bio-
marker is available to either rule out or confirm causality, 
and assignment to a specific HDS ensues via exclusion of 
other causes. Causality assessment, the process of deter-
mining whether there is a reasonable likelihood that a drug 
or HDS is the cause of liver injury, is performed gener-
ally using one of several assessment methods (Maria and 
Victorino 1997; Aithal et al. 2000; Rochon et al. 2008). 
Determination of causality of toxicity for HDS in general 
and for herbal hepatotoxicity in particular is usually not 
an easy task and especially when such agents contain sev-
eral ingredients with an origin which is not always easy to 
trace. Regardless of these limitations, such methods have 
been employed for determining causality for liver injury of 
conventional medications as well as of HDS, but there has 
not been a distinctive or formal method developed to assess 
causality for liver injury attributable to HDS. Importantly, 
the assessment must be conducted in a carefully defined 
and methodical fashion (Fig. 1).
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Quality and safety assurance of herbal products
The rapidly expanding use of herbal products and espe-
cially those used as HDS has put quality and safety assur-
ance of such compounds in the focus of attention of the 
scientific community and regulatory authorities world-
wide (Chang 1999; Fu et al. 2009; Vlietinck et al. 2009; 
Goodarzi 2013; Alaerts et al. 2014; Regev 2014; Decon-
inck et al. 2015). Good agricultural practice (GAP) and 
good manufacturing practice (GMP) guidelines and use of 
reference reagents should be the corner stones for stand-
ardization of manufacturing of HDS. However, regulatory 
control using such procedures is still not enforced univer-
sally. Chromatographic techniques are available to assess 
the quality of individual herbs and to screen for adulterants. 
Yet, interpretation of results obtained through such proce-
dures is often difficult, especially when testing large mix-
tures of herbs and pharmacologic agents which may also 
interact among themselves. It has been suggested that in 
case of an investigation regarding potential hepatotoxic-
ity of a particular product, the minimal information used 
for quality assurance should include: identification of the 
manufacturer’s address, phone and fax number, as well as 
email address; expiration date of the product; batch num-
ber; detailed recommendations for indications and con-
traindication; daily dose and maximum duration; correct 
labeling of all ingredients; accurate definition of plant fam-
ily and plant part; definition of solvents, solubilizers, and 
excipients; assurance for consistency from batch to batch as 
well as regulatory approval. Regretfully, such information 
is often unavailable to the investigator. The EU has recently 
proposed a simplified procedure allowing the registration 
of herbal medicinal products. Thus, the quality and safety 
of herbal products will be determined by employment of 
agreed upon analytical procedures published in the Euro-
pean Pharmacopoeia and supervised by the European Med-
icines Agency (EMEA) (Vlietinck et al. 2009). The current 
regulatory status of herbal products in the USA, Canada, 
the UK, and some Asian countries is reviewed in reference 
(Seeff et al. 2014).
HDS associated with liver injury
HDS may cause liver injury similar to that attributed to 
conventional synthetic drugs, and clinical presentation can 
be highly variable, even with the same product. Likewise, 
there is no recognized uniform mechanism by which liver 
injury is precipitated, and predisposing risk factors are 
identified for only a minority of preparations. Due to these 
similarities, clinical signs and laboratory findings are often 
falsely ascribed to other putative hepatotoxic drug before 
HDS or self-prepared herbals are suspected. Pivotal to cor-
rectly diagnosing HDS as the underlying cause of DILI 
is the investigator’s awareness and suspicion leading to a 
thorough drug history with specific interrogation for the 
intake of “natural,” “herbal,” or unconventional medica-
tion. No specific laboratory tests are available to prove or 
rule out HDS (and most synthetic drugs) as the cause of 
liver injury. Performing a liver biopsy may be justified, but 
histopathology reports often turn out to be at best “compat-
ible” with DILI, which does not aid to dissect conventional 
drugs from herbals as the cause of DILI.
The following description is a brief summary of HDS 
associated with DILI according to the literature to date. For 
a better structure, we deliberately separated herbals from 
dietary supplements although both sometimes overlap. 
Evidence in most cases is based on single of series of case 
reports, and systematic cross-sectional, population-based, 
or even prospective studies are rare. An overview of herb-
als and defined HDS that have been associated with liver 
damage is provided in Table 2. Regular updates on drugs or 
xenobiotics associated with liver damage can be found on 
internet-accessible Web sites (http://livertox.nih.gov/; Zhu 
and Kruhlak 2014).
Herbals containing pyrrolizidine alkaloids
Several thousands of cases of pyrrolizidine alkaloid (PA)-
induced cases of liver injury have been reported worldwide 
(Lin et al. 2011). Pyrrolizidine alkaloids (PAs) such as 
symphytine, echimidine, seneciophylline, retronescine, and 
monocrotaline are contained in extracts from common heli-
otrope (Heliotropium), ragwort (Senecio), comfrey (Sym-
phytum officinale), Crotalaria species, and the Chinese 
medicine ‘Tusanqi’ (Gynura segetum) to name only a few 
examples. While comfrey is used as the active ingredient 
Paent with liver abnormality
Suspicion
Hepatotoxic potenal of the drug
Temporal circumstances






Search for confirmatory findings
(host factors, lab findings, liver biopsy,
causality scores)
Fig. 1  Establishing causality in DILI due to HDS is complex and 
involves a high degree of suspicion and searching of the literature. 
No confirmatory tests are available, and diagnosis is often made by 
exclusion of other non-DILI causes of liver abnormalities. Useful are 
causality scores established for DILI due to synthetic drugs
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of commercial tinctures and ointments available in phar-
macy shops to treat bruises and joint injuries, while oral PA 
preparations are banned in Europe and Northern America. 
Exposure of humans to other PA-containing herbals rather 
occurs via contaminated foodstuff such as salads, cereals, 
and even honey, or and only rarely by therapeutic intention 
(Prakash et al. 1999).
A clinical syndrome described as ‘Senecio disease’ in 
South Africa including ascites, hepatomegaly, and cirrhosis 
in some patients (Wilmot and Robertson 1920), and reports 
of cases from Jamaica about children presenting similar 
symptoms after the ingestion of ‘bush tea’ made from Cro-
talaria (Bras et al. 1954) are among the earliest reports. 
Contamination of gondli, a wide-used crop with Heliotro-
pium, was the reason for remarkable series of PA intoxica-
tions in India (Tandon et al. 1976) and Afghanistan (Kakar 
et al. 2010). In Western countries, several reports, some 
of which in infants, describe serious liver damage after 
the consumption of herbal tea made of ragwort (Senecio 
longilobus) and Alpendost (Adenostyles alliariae) (Stillman 
et al. 1977; Sperl et al. 1995). A hitherto undescribed syn-
drome termed Hirmi Valley liver disease was first reported 
in 2001 in Tigray, Ethiopia, with 591 cases of which 228 
died (Robinson et al. 2014). Clinical presentation included 
abdominal pain and distension due to ascites, bloody diar-
rhea, and hepatosplenomegaly. Liver injury was ascribed to 
the PA acetyllycopsamine detected in stored grain, which 
in combination with the pesticide DDT (dichlorodiphenyl-
dichloroethylene) produced either acute injury character-
ized by centrilobular necrosis or chronic injury with bile 
ductular reaction, cytomegaly, and fibrosis.
PA exerts a clear dose-dependent hepatotoxicity, and the 
characteristic type of liver injury provoked by PA is sinu-
soidal obstructive syndrome (SOS), previously referred to 
as veno-occlusive disease. In SOS, a non-thrombotic oblit-
eration of the lumen of the terminal centrilobular hepatic 
veins results in venous outflow obstruction, consecutive 
hepatic congestion, and parenchymal necrosis. However, 
some PA may also cause hepatocellular necrosis with-
out vascular lesions (Robinson et al. 2014). Clinical pres-
entation can be either acute up to fulminant liver failure 
or chronic with progressive liver fibrosis and cirrhosis 
and the majority of patients reveal ascites (DeLeve et al. 
2002). Imaging tests with computed tomography or mag-
netic resonance tomography can be variable with patchy 
liver enhancement and main right hepatic vein narrowing 
or occlusion (Zhou et al. 2014). However, SOS can also 
present as a liver mass mimicking a primary or secondary 
hepatic malignancy (Ng et al. 2014). Treatment of affected 
patients is symptomatic, and after cessation of PA intake, 
spontaneous recovery PA is possible. Injury occurs due to 
direct toxic effects from PA transformed into pyrrole deriv-
atives by microsomal P450 enzymes (Mei et al. 2010), and 
inducers of cytochrome P450 3A4, 2B6, and several iso-
enzymes of the 2C family may enhance PA toxicity. Acute 
toxicity is not species specific, and an animal model of 
SOS using monocrotaline has been characterized (DeLeve 
et al. 1999).
Chinese herbs
Herbal medicine as part of traditional Chinese medicine 
(TCM) dates back as far as 2100 B.C., and the rising popu-
larity of oriental medicines in general has promoted its use 
worldwide. Traditionally, most Chinese medicines are mix-
tures of several different herbs of which one or two are con-
sidered the pharmacologically active “King herbs,”while 
the remaining constituents are intended to modulate the 
effect of the King herb, alleviate its toxicity, or support 
circumstances considered important for regaining health. 
More than 13,000 different herbals preparations are used 
in TCM which makes it extremely difficult to scientifically 
identify the active component or the ingredient respon-
sible for the liver injury. Active or toxic ingredients may 
Table 2  Herbal nutritional supplements associated with DILI
Product/compound Indication for use Liver pathology Toxicity mechanisms
Several Herbalife® combinations Various (weight loss, nutritional 
support, “well-being”)
Variable (acute and chronic hepati-
tis, cholestasis, cirrhosis, and 
hepatic failure)
Unknown; autoimmunity? Bacterial 
contamination?
Usnic acid (e.g. LipoKinetix®) Weight loss Acute hepatitis Uncoupling of respiratory chain?
Hydroxycut Weight loss Acute and/or cholestatic hepatitis, 
liver failure
Unknown
Anabolic steroids Sports performance, doping Cholestasis, steatosis, and peliosis 
hepatis
Inhibition of biliary transporter 
proteins
Green tea (Camellia sinensis) Weight loss Acute hepatitis Oxidative stress from (−)-epigal-
locatechin gallate?
Oxy Elite Pro Weight loss, improvement of 
physical performance
Acute and fulminant hepatitis Unknown
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vary when plants are harvested during different seasons or 
extracted through variable procedures. Also, contamination 
of herbals with microorganisms, pesticides, heavy metals, 
fungal toxins such as aflatoxin, and synthetic drugs has 
been described (Efferth and Kaina 2011).
The Chinese herb Jin Bu Huan extracted from Lypoco-
dium serratum (Creeping Cedar) was widely used in the 
USA during the 1990s for mild sedative effects. During 
that time, a total of 11 cases of both acute and chronic hep-
atitis (Woolf et al. 1994; Piciotto et al. 1998) and several 
reports of cardiorespiratory misadventures were published 
(Horowitz et al. 1996). Liver enzyme elevations normalized 
upon discontinuation of treatment. While the sedative prop-
erties are due to laevo-tetrahydropalmatine which harbors 
opiate-like properties, the toxic mechanism by which liver 
injury is precipitated remains unknown. Laevo-tetrahydro-
palmatine shares structural similarities to PA; however, 
liver histology from Jin Bu Huan typically shows focal 
necrosis and portal fibrosis, but no features of SOS.
A number of HDS marketed for weight loss in the USA 
contained Ma-Huang (Ephedra sp.). Besides cardiotoxicity, 
several published incidents demonstrated as risk of hepato-
toxicity from Ma-Huang with acute hepatitis quickly after 
intake, sometimes with elevated autoantibodies, suggesting 
drug-induced autoimmunity (Nadir et al. 1996; Neff et al. 
2004; Vigano et al. 2008). Another series showed an asso-
ciation of Ma-Huang hepatotoxicity with genotype C282Y/
H63D within the HFE gene, but this link has not been con-
firmed (Bajaj et al. 2003).
Several cases of acute hepatitis and even fulminant 
hepatic failure with a fatal course in two subjects were 
reported from studies investigating the efficacy of com-
binations of several Chinese herbals used to treat atopic 
dermatitis (Kane et al. 1995; Yoshida et al. 1996; McRae 
et al. 2002). The majority of used combinations contained 
common peony (Paeonia officinalis) and/or Dictamnus 
(Dictamnus dasycarpus), but the causative component 
remained unclear. Regarding the latter, a single series of 
four cases of acute hepatitis was reported from Korea com-
mencing after the intake of a decoction made by boiling 
down the root of Dictamnus dasycarpus. Liver injury sub-
sided in all cases after cessation of intake (Jang et al. 2008).
A remedy formulated from the roots and vines of Polyg-
onum multiflorum, termed “Shou-Wu Pian,” is used as a 
treatment for dizziness, hair loss, constipation, and inter-
estingly, as a “liver tonic.”. Since the first report on a case 
of acute hepatitis in a 31-year-old pregnant woman in 1996 
(But et al. 1996), numerous larger series of cases confirmed 
its potential to cause liver injury including liver failure 
mainly in China and Korea where “Shou-Wu Pian” is used 
manifold as an antiaging tonic to treat tinnitus and to pre-
vent premature greying of hair, lumbago, and constipation 
(But et al. 1996; Park et al. 2001; Mazzanti et al. 2004; 
Panis et al. 2005; Cárdenas et al. 2006; Laird et al. 1998; 
Jung et al. 2011; Dong et al. 2014; Ma et al. 2014). It has 
been speculated that toxicity may be related to anthraqui-
nones, which are known constituents of Polygonum multi-
florum, but this hypothesis has not been proven.
Breynia officinalis, a species of Euphorbiaceae, has long 
tradition in China as a treatment of contusions and bruises, 
heart failure, venereal diseases, growth retardation, and 
conjunctivitis, sometimes in combination with other tradi-
tional Chinese herbals. The first cases of liver injury from 
this herbal were identified in Taiwan involving two women 
with acute cytolytic hepatitis (Lin et al. 2002), followed by 
a larger series of 19 poisonings which occurred after the 
consumption of a soup cooked with Breynia officinalis, 
accidentally mistaken for a similar plant, Securinega suf-
fruticosa (Lin et al. 2003). No cases outside Taiwan have 
been reported to date.
Germander
A prominent example of a HDS approved as a weight loss 
remedies is germander (Teucrium chamaedrys) which was 
licensed and distributed as capsules and tea bag prepara-
tions in France in the early 1990 s. Numerous reports to 
the French pharmacovigilance authorities in 1992 about 
germander-associated acute, chronic, and even fulminant 
hepatitis (Larrey et al. 1992) were recorded. Typically, 
liver injury presented as acute cytolytic hepatitis, but some 
patients with a chronic course of liver disease were also 
recorded revealing histologic features of chronic hepatitis 
with fibrosis and even cirrhosis. Causality assessment link-
ing germander and liver damage is undisputed after several 
incidents of accidental re-exposure followed by immedi-
ate relapse of liver injury. However, all patients recovered 
after discontinuation of the herbal except for those with 
cirrhosis. French pharmacovigilance authorities banned 
germander products and no further cases were recorded. 
However, two recent cases were recorded in Italy of a mar-
ried couple who developed acute hepatitis after ingesting 
a self-made decoction containing T. chamaedrys L., with 
proven causality after voluntary re-exposure (Gori et al. 
2011).
For germander, rigorous research of toxicity in animal 
studies identified furane-containing neo-clerodane dit-
erpenoids as the precipitating compounds (Loeper et al. 
1994; Kouzi et al. 1994; Lekehal et al. 1996; Fau et al. 
1997). Formation of epoxides is enhanced by induction of 
cytochrome P450 3A and by glutathione depletion, which 
may occur during weight loss or regular alcohol consump-
tion. In France, all preparations containing T. chamaedrys 
L. as herbal medicine are revocated, while the US. Food 
and Drug Administration permits T. chamaedrys L. extracts 
at low levels in alcoholic beverages only.
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Another member of the Teucrium labiatae, T. polium 
(Felty Germander or Hulwort), has been shown to cause 
fulminant hepatic failure following its ingestion as an anti-
inflammatory and antimicrobial drug and for the treatment 
of scars (Mattei et al. 1995; Savvidou et al. 2007). There 
is also a single report of acute hepatitis with jaundice 
that occurred in a patient who took a traditional Chinese 
remedy containing Teucrium viscidum for back pain that 
resolved spontaneously after the remedy had been stopped 
(Poon et al. 2008).
Chapparal
Chaparral (Larrea tridentata) is a traditional herbal remedy 
among Native Americans who refer to it as Creosote Bush 
or Greasewood to treat common cold, bone and muscle 
pain, and snake bites. Like with many herbals once adopted 
by Western societies, commercial products containing 
Chaparral were mainly sold for alleged weight-reducing 
properties, and for presumed anti-inflammatory, antioxidant 
and “blood-purifying” benefits. Furthermore, patients with 
human immunodeficiency virus infection turned to Chapar-
ral as part of their adjuvant self-medication (Kassler et al. 
1991). In the 1990s, the FDA recorded a series of cases of 
Chaparral-related hepatotoxicity ranging from mild eleva-
tions of serum liver enzyme concentrations to fulminant 
hepatitis with subsequent liver transplantation for hepatic 
failure in two cases (Sheikh et al. 1997). Although chole-
static hepatitis accounted for the majority of cases, there 
were also chronic sequels with cirrhosis. Larrea tridentata 
was found in all preparations, and biochemical and micro-
bial contamination was excluded. A causal relationship 
was postulated based on the temporal correlation between 
intake of Chaparral and the onset of liver disease, a con-
sistent pattern of hepatic damage, and through the obser-
vation that reexposure to Chaparral or an increased in its 
dose led to relapse or aggravation of clinical signs of liver 
disease. While the magnitude of cases was noticed in 
Northern America, Kauma and coauthors described a case 
of a previously healthy woman in Finland who developed 
severe acute hepatitis after the intake of chaparral tablets 
(Kauma et al. 2004). Chaparral toxicity is likely due to nor-
dihydroguaiaretic acid which inhibits cyclooxygenase and 
cytochrome P-450 (Agarwal et al. 1991).
Actractylis gummifera and Callilepsis laureola
Extracts of A. gummifera have been used traditionally as 
a natural antipyretic, emetic, diuretic and as chewing gum 
by children in North Africa and the Mediterranean. Some-
times, ingestion occurs when A. gummifera is confused 
with wild artichoke, and cutaneous application also appears 
to carry a risk of inducing liver injury (Bouziri et al. 2010). 
Acute onset of toxic hepatitis with potentially fatal hepato-
renal failure is well described and associated with severe 
neurovegetative symptoms and pronounced hypoglycemia 
(Georgiou et al. 1988; Hamouda and Hédhili 2004). Spo-
radic cases are still occasionally recorded until recently 
advocating the demand for education on the potential risks 
of using A. gummifera (Mouaffak et al. 2013). Consump-
tion of A. gummifera is particularly dangerous during 
spring time when toxins are highly concentrated in roots.
A traditional herbal remedy used among the Zulu people 
in South Africa is called Impila which contains Callilepsis 
laureola as the major constituent. Impila is the Zulu word 
for “health” and is used as a multi-purpose treatment for 
stomach problems, impotence, infertility, and to deter “evil 
spirits.” However, a series of incidents substantiate evi-
dence for potentially lethal nephro- and hepatotoxicity of 
C. laureola (Popat et al. 2001). Particularly, worrisome is 
a large series of children identified retrospectively as hav-
ing died from C. laureola intoxication who presented with 
a clinical picture similar to Reye’s syndrome with acute 
hepatorenal failure, hypoglycemia, and multi-organ bleed-
ing (Watson et al. 1979). Autopsy examinations showed 
centrilobular zonal necrosis of the liver, tubular renal necro-
sis, and hemorrhages in lungs, skin, and intestine. Despite 
its well-known toxicity, the underlying mechanism is only 
partly understood. Animal studies in rats indicate that 
atractyloside and carboxy-atractyloside are potent inhibi-
tors of oxidative phosphorylation and other mitochondrial 
functions, which may lead to uncoupling of the respiratory 
chain and subsequent apoptosis (Stewart et al. 2002). Popat 
et al. (2002) have shown that Impila extracts cause a con-
centration- and time-dependent loss in cell viability and 
mitochondrial glutathione (GSH) content in HepG2 cells 
preventable with N-acetylcysteine and S-adenosyl-L-me-
thionine, precursors of GSH. Whether treatment of intoxi-
cated subjects is beneficial, is unknown until know, and 
novel cases of Impila intoxication have not been published 
for the past 15 years.
Pennyroyal
A relatively rare cause of liver damage is that associated 
with Pennyroyal, also referred to as “squawmint oil.” Its 
traditional use is as a natural abortifacient and deterrent 
against fleas. Pennyroyal is made of leaves from either 
Mentha pulegium or Hedeoma pulegoides and has long 
been identified as a cause of severe acute liver injury (Poon 
et al. 2008). Several reports of fulminant hepatic necrosis 
due to Pennyroyal with lethal outcome have been described 
(Sullivan et al. 1979; Anderson et al. 1996). Its primary 
constituents are pulegone and various other monoterpenes 
characteristically contained in mint species. Hepatotox-
icity appears to be due to depletion of GSH by pulegone, 
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consecutive enhanced oxidative stress, and via pulegone’s 
primary metabolite menthofuran which is transformed 
through cytochrome P450 into a hepatotoxin (Bakerink 
et al. 1996; Thomassen et al. 1990; Thomassen and Knebel 
1992; Gordon et al. 1987).
Greater chelandine
Preparations containing greater celandine (Chelidonium 
majus) were widely used in Europe to improve bile flow 
and in the treatment of irritable bowel syndrome although 
the clinical evidence supporting its use for these indications 
was far from robust. Greater celandine contains at least 20 
different alkaloids including berberine, coptisine, cheler-
ythrine, and chelidonine, of which the latter compound is 
measured to standardize the extract. Several reports from 
European countries have described its potential to precipi-
tate liver injury (Benninger et al. 1999; Crijns et al. 2002; 
Stickel et al. 2003; Hardeman et al. 2008; Moro et al. 
2009). The largest series of 10 patients revealed cholestatic 
hepatitis together with low titers of autoantibodies suggest-
ing drug-induced autoimmunity after variable periods of 
ingestion of different greater celandine preparations (Ben-
ninger et al. 1999). However, the exact mechanism respon-
sible for injury remains unclear and efforts to develop an 
animal model have thus far failed. With effect of April 9, 
2008, approval of all preparations containing more than 
2.5 mg of chelidonine was revocated in Germany. Up to 
2011, 124 cases of adverse hepatic reactions associated 
with the use of greater celandine had been reported to the 
Vigisearch database of the World Health Organisation in 
Uppsala. As a consequence, the Herbal Medicinal Products 
Committee (HMPC) of the European Medicines Agency 
(EMA) released a public statement on the use and safety 
of Chelidonium majus and concluded “…that evidence of 
clinical efficacy was lacking for monotherapy and thus a 
well-established use indication was not supported. The 
HMPC considered the documented traditional uses for 
Chelidonium majus, but concluded that in the presence 
of a high number of spontaneously reported hepatobiliary 
adverse drug reactions and the withdrawal of products in 
Member States due to safety concerns, the benefit–risk 




A prominent example of severe hepatotoxicity from a 
herbal drug is Kava-associated liver injury. While Kava 
root (Piper methysticum rhizoma) has long been used 
as a traditional psychotropic remedy in Hawaii, Polyne-
sia and the Fiji Islands, Kava-containing preparations are 
marketed in industrialized countries for the treatment of 
anxiety disorders and depression. Sedative activity is due 
to kavapyrones, including kavain, dihydrokavain, methys-
ticin, dihydromethysticin, which act via inhibitory gamma-
amino-butyric acid receptor in the reticular formation and 
the limbic system (Davies et al. 1992; Jussofie et al. 1994). 
Scientific evidence supporting its anxiolytic and antide-
pressive efficacy is relatively good compared with other 
herbals as shown by a recent systematic review and meta-
analysis of randomized, controlled trials with Kava for the 
treatment of anxiety (Pittler and Ernst 2000). A detailed 
analysis of 29 cases of adverse hepatic reactions due to 
Kava in Germany using a clinical causality score reported 
liver injury with both alcoholic and acetonic Kava extracts 
(Stickel et al. 2003). The large majority of patients were 
females who developed cytolytic or cholestatic hepatitis, 
and nine patients developed fulminant liver failure with 
subsequent liver transplantation in eight of the patients. 
Three patients died, two following unsuccessful liver trans-
plantation. The remaining patients all recovered completely 
after the withdrawal of Kava. Until recently, more than 100 
cases of liver damage have now been associated with Kava 
worldwide which is comparable with numbers that have 
led to the banning of synthetic drugs. The mechanism by 
which liver injury is precipitated is still unclear since no 
dose–response pattern can be recognized. However, some 
patients took doses exceeding several times the recom-
mended daily dose of 120 mg. For most other patients, both 
the cumulative dose and the latency until the hepatotoxic 
reaction emerged were highly variable suggesting drug idi-
osyncrasy. Along this line, a poor metabolizer phenotype of 
cytochrome P450 2D6 was suggested as a risk factor for 
developing Kava-related liver damage (Russmann et al. 
2001). Another possible basis for its toxicity relates to the 
mode of Kava extraction, with recent in vitro and animal 
studies confirming that aqueous kava extracts are less cyto-
toxic than organic solvent fractions (Jhoo et al. 2006; Sor-
rentino et al. 2006). It also had been speculated that Kava 
had been safely used in its tradition way, while toxicity had 
only been observed with commercial products, but acute 
hepatocellular injury has also been described in association 
with traditional use (Russmann et al. 2003; Christl et al. 
2009). Nevertheless, accounting for the reports of liver 
damage by Kava products, the approval to distribute Kava 
products was withdrawn in the USA, Europe, and Australia 
(Centers for Disease Control and Prevention 2003).
Black cohosh (Actaea racemosa; formerly Cimifuga 
racemosa)
Black cohosh is a popular herbal from North America fre-
quently used for the treatment of menopausal symptoms 
although its efficacy is not well demonstrated (Leach et al. 
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2012). A number of reports on liver injury in Australia and 
North America described a wide range of liver injury rang-
ing from mild serum aminotransferase elevations to several 
cases of fulminant hepatic failure leading to liver transplan-
tation (Whiting et al. 2002; Levitsky et al. 2005; Pierard 
et al. 2009; Lim et al. 2013). Some patients present with 
features resembling autoimmune hepatitis such as elevated 
autoantibodies or skin rashes. In response to these reports, 
the Dietary Supplement Information Expert Committee of 
the US Pharmacopeia’s Council of Experts analyzed infor-
mation from human clinical case reports, adverse event 
reports, animal pharmacological and toxicological data, 
historical use, regulatory status, and contemporaneous 
extent of use associated with black cohosh (Mahady 2008). 
All 30 individual reports of liver damage available to that 
time were received levels of causality of “possible,” but 
none were labeled “probable” or “certain.” Based on these 
results, it was concluded that black cohosh products should 
be labeled with a cautionary statement indicating that hepa-
totoxicity is a possible adverse outcome. How toxicity may 
occur is not fully elucidated, but experimental data are sug-
gestive of mitochondrial damage and subsequent apoptosis 
(Lüde et al. 2007).
Miscellaneous
Various other botanicals have been associated with toxic 
liver damage such as Senna (Cassia angustifolia), which 
is used as a laxative. Since the first case in a woman who 
developed relatively benign hepatitis taking approximately 
ten times the recommended dose with positive rechallenge 
(Beuers et al. 1992), two more incidents were published 
which showed portal vein thrombosis in one (Soyuncu 
et al. 2008), and acute liver failure in another case (Van-
derperren et al. 2005). However, in all cases, long-term 
consumption of either self-manufactured or high doses of 
Senna was recorded.
Nadir et al. (2000) have described a man in whom short-
term use of a commercial Cascara sagrada product caused 
cholestatic hepatitis with subsequent portal hypertension, 
prolonged prothrombin time, and ascites. Cascara sagrada 
contains anthraquinone glycosides and is recognized as an 
effective laxative. Further laboratory tests revealed elevated 
antinuclear and antismooth muscle antibody titers of 1:640 
and 1:40, respectively, and a liver biopsy showed an eosin-
ophilic infiltrate suggesting drug-induced autoimmunity.
Another combination of herbal ingredients, known as 
“Prostata,” was suspected to have caused cholestatic hep-
atitis in a man using this medication for the treatment of 
benign prostatic hyperplasia (Hamid et al. 1997). The pre-
sumed active ingredient Serrenoa serrulata exerts estro-
genic and antiandrogenic effects, and either hormone may 
cause liver injury under certain circumstances.
In Ayurvedic medicine, the herbal Centella asiatica is 
named Gotu Kola and has been used as a psychophysical 
regenerator and “blood purifier,” and for a plethora of indi-
cations comprising dementia, diabetic microangiopathy, 
skin defects, and obesity (Brinkhaus et al. 2000). Recently, 
three female patients who took this herbal for periods of 
between 1 and 6 months to lose weight, developed severe 
hepatic injury, including granulomatous hepatitis and cir-
rhosis (Jorge and Jorge 2005). Unintentional re-exposure 
resulted in accelerated recurrence of hepatic lesions in two 
of the patients and treatment with ursodeoxycholic acid 
at 10 mg/kg/day led to normalization of altered liver bio-
chemistries in all three patients. Further cases have been 
described, even in children (Dantuluri et al. 2011; Chitturi 
and Farrell 2008). Extracts of this herb contain pentacyclic 
triterpenic saponosides including asiaticoside, madecasso-
side, and centellasaponins. The mechanism by which liver 
damage is precipitated is uncertain.
Noni juice (Morinda citrifolia) has been associated with 
possible liver toxicity in a case series of seven patients, 
among which one patients developed fulminant hepatic 
failure leading to liver (Stadlbauer et al. 2008; Yu et al. 
2011). In the less severe cases, liver tests rapidly returned 
to normal after the termination of Noni intake. Since these 
incidents, additional cases were reported (Waldman and 
Piotrowicz 2013; Mrzljak et al. 2013). Active components 
within Noni extracts include flavonoids, glycosides, vita-
mins, polyunsaturated fatty acids, and anthraquinones. 
Which and how components within Noni cause liver injury 
is unknown.
Glucosamine/chondroitine preparations easily obtained 
over the counter are popular dietary supplements used for 
osteoarthritis and distributed as tablets, capsules, powder, 
or liquid. Rare cases of acute, mainly hepatocellular injury, 
sometimes mimicking (seronegative) autoimmune hepatitis 
have been reported in patients receiving either glucosamine 
alone or in combination with chondroitine sulfate (Cerda 
et al. 2013; von Felden et al. 2013). Causality assessment 
to intake of glucosamine or the combination with chondroi-
tine sulfate, although confounded by intake of other drugs 
or herbals, varied between possible to probable.
Herbal dietary supplements associated with liver injury
Green tea (Camellia sinensis)
Green tea has been consumed for centuries and is currently 
among the most popular drinks in the world. After the first 
report on liver injury following the ingestion of green tea 
preparations in 1999 (Stickel et al. 2011), more than 60 
case reports of hepatotoxicity associated with the con-
sumption of green tea extracts, powdered leaves, green tea 
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infusions, and hydroalcoholic and aqueous extracts have 
been recorded (Patel et al. 2013; Weinstein et al. 2012). The 
US Pharmacopeia systematically reviewed a subset of cases 
from North America, Great Britain, and Australia published 
until 2008 of liver injury following the ingestion of various 
different green tea preparations (Sarma et al. 2008). Among 
thirty-four evaluated cases including one lethal case, seven 
reports pertaining to liver damage were labeled as “prob-
ably,” and the remaining seven cases as “possibly” linked to 
green tea. Liver histology revealed severe necro-inflamma-
tion and biliary injury. However, caution is advised about 
blaming liver injury on the green tea alone in some of the 
reported cases; since in many instances, the patients also 
took other products that have been implicated in causing 
hepatotoxicity such as Cassia angustifolia (see above), 
Hydroxycut, usnic acid (Yellapu et al. 2011), and Ephe-
dra sinica (for all, see below). The background of toxicity 
caused by green tea is uncertain but could relate to (−)-epi-
gallocatechin gallate (EGCG) or its metabolite (−)-epicat-
echin gallate (ECG) which, under certain conditions such 
as fasting, can induce oxidative stress and thus liver dam-
age (Galati et al. 2006). In contrast, however, is that in vitro 
and in vivo experimental studies have also demonstrated 
hepatoprotective properties for green teas (Lin et al. 2009; 
Zhong et al. 2003), and a recent systematic review of clini-
cal studies aimed at defining the therapeutic effects of C. 
sinensis in humans found overall favorable effects from the 
tea as reflected by reduced mortality, attenuated steatosis, 
and a reduced incidence of primary liver cancer (Jin et al. 
2008). Structured causality assessment suggests a causal 
relationship between intake of green tea-containing prod-
ucts and liver injury, but whether the risks from green tea 
consumption outweigh their benefits remains unresolved so 
far.
Herbalife
Herbalife™ is a US-based company with an annual turnover 
of 4.825 billion $ which distributes numerous products for 
weight control, dietary supplements, and cosmetics through 
online marketing and independent sales persons. Altogether, 
there are seven published reports describing 54 cases from 
Switzerland, Israel, Spain, Argentina, and Iceland of sig-
nificant liver injury following consumption of Herbalife™ 
HDS (Elinav et al. 2007; Schoepfer et al. 2007; Duque et al. 
2007; Chao et al. 2008; Stickel et al. 2009; Johannsson 
et al. 2010; Manso et al. 2011). The patterns of injury were 
mostly hepatocellular, but cases with mixed and cholestatic 
enzyme patterns were also observed. Severity varied from 
mild to severe acute and chronic liver damage including cir-
rhosis and acute liver failure requiring liver transplantation. 
Generally accepted drug-induced liver injury (DILI) assess-
ment scoring systems were used in evaluating most of the 
cases, seven of whom were considered “certain” because of 
a positive re-challenge, while most of the remaining cases 
were scored as “probable.” Identification of the mechanism 
by which liver injury was caused is notoriously difficult 
since the majority of patients took up to 17 different Herbal-
ife® products at the same time. In addition to the possibility 
that autoimmune mechanisms played a role in inducing the 
liver injury among those who had elevated titers of autoan-
tibodies and plasma cell infiltrates in their liver biopsies, 
adulteration of individual batches with bacterial pathogens 
may explain some other cases in view of a report that two 
patients were found to have bacterial contamination of sev-
eral Herbalife® products with Bacillus subtilis and Bacillus 
cereus (Stickel et al. 2009). The sporadic presentation of 
Herbalife reported that hepatotoxicity requires an explana-
tion. Herbalife® runs numerous production sites worldwide. 
Spoiled products may have been contaminated with certain 
germs or chemicals such as softeners, preservatives, flavor 
enhancers, pesticides, or heavy metals added either during 
the manufacturing process or by using unrefined raw prod-
ucts, i.e., herb extracts. These could have been responsible 
for local series of cases of hepatotoxicity and batch-to-batch 
variation. Interestingly and so far, no further cases have 
been observed after the latest series from Spain in 2011 
(Manso et al. 2011).
Usnic acid
Usnic acid extracted from lichens and fungi have been 
marketed as HDS in the USA to aid in weight loss. Effi-
cacy for this indication was postulated based on its func-
tion as an uncoupler of the respiratory chain. Uncouplers 
of mitochondrial oxidative phosphorylation have gained 
attention as possible ingredients for weight loss supple-
ments because they are believed to increase metabolic rates 
and stimulated fuel oxidation which in principle can aug-
ment weight loss (Moreira et al. 2013). However, it may 
also cause mitochondrial injury and subsequent hepato-
cyte death (Han et al. 2004). Several cases of acute liver 
failure have been reported requiring liver transplantation 
following the intake of LipoKinetix®, a product contain-
ing norephedrine (also known as phenylpropanolamine or 
PPA), caffeine, yohimbine, diiodothyronine, and sodium 
usniate (usnic acid), and sold as HDS capsules (Favreau 
et al. 2002; Durazo et al. 2004; Sanchez et al. 2006). Liver 
injury usually commenced acutely within the first 3 months 
of intake and showed a hepatocellular pattern with massive 
elevations of ALT and AST levels. None of the ingredients 
were previously associated with liver damage, and inad-
vertent contamination was excluded. As a consequence, 
the US FDA issued a warning about LipoKinetix in 2001 
(Jin et al. 2008), and the product was withdrawn from the 
market.
861Arch Toxicol (2015) 89:851–865 
1 3
Hydroxycut
Another panel of commercial HDS product associated with 
liver injury, including cases with acute hepatic failure and 
subsequent liver transplantation, were several Hydroxy-
cut® products containing Garcinia cambogia, Gymnema 
sylvestre, chromium polynicotinate, caffeine, and green tea 
(Steven et al. 2005; Jones and Andrews 2007; Dara et al. 
2008; Shim and Saab 2009; Fong et al. 2010). Hydroxy-
cut preparations were sold to support weight loss and mus-
cle built-up by conventional retailers, via internet sources, 
and by direct television marketing. The clinical presenta-
tion characteristically shows an acute onset after weeks of 
intake, presenting with high levels of serum transaminase 
values in most cases, while others presented more insidi-
ously with cholestasis. Following a warning posted by the 
FDA in May 2009, products HDS associated with DILI 
were withdrawn by the manufacturer in 2009 (http://www.
fda.gov/Safety/recalls/ucm/1451).
Anabolic steroids
Anabolic steroids are somehow different from the HDS 
described above as they are classified as class III sub-
stances, strictly regulated, and banned from amateur and 
professional sports activities. However, anabolics ster-
oids are used by recreational or professional bodybuild-
ers to improve fitness, to trim their muscle built-up, and 
to increase their exercise performance, often via obscure 
sources. Hepatotoxicity is well described, and patterns of 
injury include cholestasis, hepatitis, hepatocellular ade-
noma and even hepatocellular carcinoma, and a rare path-
ological entity termed peliosis hepatis characterized by 
the appearance of multiple cyst-like, blood-filled cavities 
within the liver (Ishak 1981; Erlinger 1997).
The most frequently seen injury, however, is choles-
tatic liver injury, often after the anabolic steroid has been 
stopped (Shah et al. 2008). Sometimes multi-ingredient 
HDS contain anabolic steroids sufficient to precipitate even 
severe liver injury (Kafrouni et al. 2007; Krishnan et al. 
2009). The precise mechanism of toxicity is yet unclear, 
but findings from genotyping of patients who developed 
cholestasis after taking anabolic steroids suggest that ana-
bolic steroids may cause inhibition of biliary transporter 
proteins such as ATP8B1/ABCB11, thereby triggering ini-
tial episodes of benign recurrent intrahepatic cholestasis 
(BRIC) type 1/or 2 (El Sherrif et al. 2013).
A recent case control study from Brazil suggested that 
anabolic steroids could be a cause of toxicant-associated 
non-alcoholic fatty liver disease (TAFLD). In 12.6 % of 
subjects consuming anabolic steroids, criteria compat-
ible with TAFLD such as steatosis on ultrasound imaging, 
elevated serum transaminases, and exclusion of relevant 
alcohol intake concomitant medication, and overweight or 
insulin resistance, were found. In contrast, 2.4 % of body-
builders not using anabolic steroids showed clinical signs 
and findings suggestive of NAFLD (Schwingel et al. 2011).
1,3-Dimethylamylamine (DMAA) and OxyELITE
OxyELITE Pro, advertised for weight loss and muscle 
building, is a multi-ingredient HDS previously implicated 
in sudden cardiac death. DMAA is a common additive in 
over 20 popular supplements advertised for body building 
and weight loss and believed to accelerate some partially 
defined metabolic processes. In 2013, the US Centers for 
Disease Control reported the results of a serious outbreak 
of liver injury verified in 29 patients from Hawai, using 
OxyELITE Pro (Centers for Disease Control and Preven-
tion 2013). Twelve patients (41 %) used only OxyELITE 
Pro, while 14 subjects used one or more dietary supple-
ments as well. Four additional cases were afterward discov-
ered through the US public health service, and seven fur-
ther cases were reported in military personnel (Foley et al. 
2014; Roytman et al. 2014). One patient died, and four 
patients underwent liver transplantation. Consequently, 
preparations containing DMAA have been banned in the 
US.
Conclusion
The use of HDS is extensive and is largely uncontrolled 
neither by pharmacovigilance authorities nor by health 
practitioners. Doctors are often confronted with an aston-
ishing persuasion that HDS products must be effective and 
safe because they are “pure” and “natural.” This prevailing 
belief is fueled by the often long-lasting tradition of herb-
als in cultures with an apparently more humane view on 
health and well-being than modern Western societies. How-
ever, much of that is wishful thinking and rather reflects 
the deep desire of consumers to avoid some of the associ-
ated adverse effects Western medicine undoubtedly has. 
As compared to conventional pharmacologic agents, safety 
and efficacy of most HDS have not been rigorously tested, 
and some of them are less safe or even hazardous. Thus, 
interrogating patients about their use is an essential diag-
nostic component when liver injury is suspected.
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